STINGagonist-3 trihydrochloride, extracted from patent WO2017175147A1 (example 10), is a selective and non-nucleotide small-molecule STING agonist with apEC₅₀andpEC₅₀of 7.5 and 9.5, respectively.STINGagonist-3 trihydrochloride has durable anti-tumor effect and tremendous potential to improve treatment ofcancer^[1].

STING^[1]

STING agonist-3 trihydrochloride exhibits a pEC₅₀value of 7.5 in activation of STING in cells, this assay is determined using a luciferase reporter assay in human embryonic kidney cells (HEK293T) co-transfected with plasmids expressing STING and the enzyme firefly luciferase driven by the interferon stimulated response element promoter^[1].
STING agonist-3 trihydrochloride exhibits a pIC₅₀value of 9.5 in FRET assay. This is a competition binding assay which aims to determine the binding potency of molecules to the C-terminal Domain (CTD) of human STING^[1].

860.19

C₃₇H₄₅Cl₃N₁₂O₆

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.